Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Heron Therapeutics, Inc. HRTX
$1.38
-$0.53 (-38.19%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
164606400.00000000
-
week52high
5.62
-
week52low
1.29
-
Revenue
107672000
-
P/E TTM
-1
-
Beta
0.89619300
-
EPS
-1.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 30 июн 2022 г. |
| Needham | Buy | Buy | 10 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 02 дек 2020 г. |
| Guggenheim | Buy | 27 мая 2020 г. | |
| Needham | Buy | Buy | 02 мар 2020 г. |
| Needham | Buy | Buy | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Szekeres David Leslie | A | 49788 | 49788 | 18 янв 2023 г. |
| MANHARD KIMBERLY | A | 149365 | 149365 | 18 янв 2023 г. |
| Peraza Lisa | A | 42631 | 42631 | 18 янв 2023 г. |
| POYHONEN JOHN | A | 66385 | 66385 | 18 янв 2023 г. |
| Quart Barry D | A | 850000 | 850000 | 18 янв 2023 г. |
| Szekeres David Leslie | D | 32500 | 4564 | 13 янв 2023 г. |
| Szekeres David Leslie | D | 8750 | 1250 | 13 янв 2023 г. |
| Szekeres David Leslie | D | 26150 | 2012 | 13 янв 2023 г. |
| Szekeres David Leslie | A | 28162 | 4564 | 13 янв 2023 г. |
| Szekeres David Leslie | A | 23598 | 1250 | 13 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2425490 | 1771 | 31 авг 2020 г. |
| SPDR S&P Biotech ETF | 2114240 | -108768 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 1878400 | 53808 | 31 авг 2020 г. |
| Franklin Growth Opportunities Fund | 2358110 | -39380 | 31 июл 2020 г. |
| Franklin Templeton Investment Funds -Biotechnology Discovery | 2287020 | 0 | 31 июл 2020 г. |
| Vanguard Small-Cap Index Fund | 2139760 | -11540 | 31 июл 2020 г. |
| Franklin Biotechnology Discovery Fund | 1739680 | 0 | 31 июл 2020 г. |
| ClearBridge Small Cap Growth Fund | 3047370 | 0 | 30 июн 2020 г. |
| Franklin U.S. Opportunities Fund (Lux) | 2627160 | 0 | 30 июн 2020 г. |
| Janus Henderson Triton Fund | 2245460 | -101943 | 31 мар 2020 г. |
Новостная лента
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.63 per share a year ago.
Why Heron Therapeutics Stock Has Been on Fire This Week
The Motley Fool
06 апр 2023 г. в 15:42
Monday, Heron announced the appointment of Craig Collard as Chief Executive Officer and Adam Morgan as Chairman. These two executives will replace outgoing CEO and Chairman Barry Quart.
Why Shares of Heron Therapeutics Jumped Thursday
The Motley Fool
06 апр 2023 г. в 14:01
Heron's cash position remains a concern. Zynrelef, the company's top-selling therapy for postoperative pain relief, had 2022 sales that were up 362%.
Heron Therapeutics, Inc. (HRTX) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 мар 2023 г. в 21:08
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chairman and Chief Executive Officer John Poyhonen – President and Chief Commercial Officer Conference Call Participants Josh Schimmer – Evercore Brandon Folkes – Cantor Fitzgerald Serge Belanger – Needham and Company Operator Good day, ladies and gentlemen. Thank you for standing by.
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
23 мар 2023 г. в 19:03
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?